The HemOnc Pulse

“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions

“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting.
This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Joseph Mikhael, MD, MEd, FRCPC, FACP, a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Research Institute, an affiliate of the City of Hope Cancer Center; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and Director of Experimental Therapeutics, Malignant Hematology at Novant Health.

"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions

"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at University of Miami Health. 

What are the Controversies Surrounding MRD in Blood Cancers?

On this episode of "The HemOnc Pulse," Alan Skarbnik, MD, of Novant Health, and Manni Mohyuddin, MBBS, of the University of Utah, discuss the concept of measurable residual disease (MRD) in hematologic malignancies and highlight the polarized views surrounding MRD.
They also weigh the implications of MRD negativity, how to harmonize the MRD threshold, and how trials are putting MRD technology to the test.

HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD

On this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS. 

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.

Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease

In this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.

Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL. 
Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation. 

Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies

Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue.
Drs. Dahiya and Spiegel return to the show shortly following the announcement that the FDA sent requests to drug manufacturers on January 9 to update prescription labels with "Black Box" warnings on the six CAR-T therapies used to treat blood cancers.
Part one of the series covers the FDA's initial report in November 2023 and why it set off a "firestorm" in the hematology-oncology community. 

Dr. Coombs Spotlights Recent CHIP Updates

In this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition.
Dr. Coombs discusses research on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as selective nuclear export inhibitors. She also illustrates another study that looks at the prevalence of CHIP in patients undergoing autologous hematopoietic stem cell transplant in lymphoma, which showed an increased risk of cardiovascular disease and lower survival rates.
 

Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk

An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.